TY - JOUR
T1 - Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women
AU - Khan, Farhan
AU - Esnakula, Ashwini
AU - Ricks-Santi, Luisel J.
AU - Zafar, Rabia
AU - Kanaan, Yasmine
AU - Naab, Tammey
N1 - Funding Information:
This project has been funded in whole or in part with Federal funds (UL1RR031975) from the National Center for Research Resources (NCRR), National Institutes of Health , through the Clinical and Translational Science Awards Program (CTSA), a trademark of DHHS, part of the Roadmap Initiative, “Re-Engineering the Clinical Research Enterprise,” (G12 RR003048) from the RCMI Program at Howard University , Division of Research Infrastructure , National Center for Research Resources , NIH and (U54 CA091431) the Howard University Cancer Center/Johns Hopkins Cancer Center Partnership , National Cancer Institute , NIH.
Publisher Copyright:
© 2018 Elsevier GmbH
PY - 2018/5
Y1 - 2018/5
N2 - Introduction: PTEN is a tumor suppressor gene that inhibits cell proliferation by inhibiting the phosphoinositide 3-kinase (PI3 K) signaling pathway. The significance of PTEN mutations resulting in variable PTEN expression and their impact on prognosis of breast cancer is not well established. The objective of our study was to correlate the immunohistochemical expression of PTEN in the four major subtypes of breast carcinoma (Luminal A, Luminal B, HER2 positive, and Triple Negative) in a population of 202 African-American (AA) females with other clinicopathological factors. Materials and methods: Tissue microarrays (TMAs) were constructed from FFPE tumor blocks from primary ductal breast carcinomas in 202 African-American females. Five micrometer sections were stained with a mouse monoclonal antibody against PTEN. The sections were evaluated for the intensity of cytoplasmic and nuclear reactivity. Bivariate analysis was done via χ2 analysis and survivability data was calculated via the generation of Kaplan-Meier curves (SPSS v19). Results: Loss of PTEN expression was associated with ER negative (p = 0.021), PR negative (p = 0.024) and triple negative (p = 0.0024) breast ductal cancers. It was marginally associated with distant metastasis (p = 0.074). There was no association between PTEN loss and recurrence-free survival or overall survival. Conclusion: In our study, a statistically significant association between PTEN loss and the triple negative breast cancers (TNBC) was found in AA women. PTEN inhibits PI3 K resulting in decreased activation of downstream effector, mammalian target of rapamycin (mTOR). Loss of PTEN results in cell proliferation through activation of mTOR. Targeted therapy with mTOR inhibitors might be useful in the treatment of TNBC.
AB - Introduction: PTEN is a tumor suppressor gene that inhibits cell proliferation by inhibiting the phosphoinositide 3-kinase (PI3 K) signaling pathway. The significance of PTEN mutations resulting in variable PTEN expression and their impact on prognosis of breast cancer is not well established. The objective of our study was to correlate the immunohistochemical expression of PTEN in the four major subtypes of breast carcinoma (Luminal A, Luminal B, HER2 positive, and Triple Negative) in a population of 202 African-American (AA) females with other clinicopathological factors. Materials and methods: Tissue microarrays (TMAs) were constructed from FFPE tumor blocks from primary ductal breast carcinomas in 202 African-American females. Five micrometer sections were stained with a mouse monoclonal antibody against PTEN. The sections were evaluated for the intensity of cytoplasmic and nuclear reactivity. Bivariate analysis was done via χ2 analysis and survivability data was calculated via the generation of Kaplan-Meier curves (SPSS v19). Results: Loss of PTEN expression was associated with ER negative (p = 0.021), PR negative (p = 0.024) and triple negative (p = 0.0024) breast ductal cancers. It was marginally associated with distant metastasis (p = 0.074). There was no association between PTEN loss and recurrence-free survival or overall survival. Conclusion: In our study, a statistically significant association between PTEN loss and the triple negative breast cancers (TNBC) was found in AA women. PTEN inhibits PI3 K resulting in decreased activation of downstream effector, mammalian target of rapamycin (mTOR). Loss of PTEN results in cell proliferation through activation of mTOR. Targeted therapy with mTOR inhibitors might be useful in the treatment of TNBC.
KW - African American
KW - Mammalian target of rapamycin (mTOR)
KW - PTEN
KW - Phosphatidyl inositol 3-kinase (PI3k)/AKT signal transduction pathway
KW - Triple-negative breast cancer
UR - https://www.scopus.com/pages/publications/85045078632
U2 - 10.1016/j.prp.2018.03.020
DO - 10.1016/j.prp.2018.03.020
M3 - Article
C2 - 29653745
AN - SCOPUS:85045078632
SN - 0344-0338
VL - 214
SP - 673
EP - 678
JO - Pathology Research and Practice
JF - Pathology Research and Practice
IS - 5
ER -